A Proposed 503B Rule Draws a Different Line From the 503A Debate

In April, the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. The agency said it did not identify a clinical need for outsourcing facilities to compound those drugs from bulk substances based on the nominations it reviewed. The agency sought public comments before a final determination.

The word "proposed" is doing important work. The announcement is not, by itself, a final exclusion. It also concerns the 503B list, which applies to outsourcing facilities; it is not a shorthand explanation of every rule that applies to a state-licensed 503A pharmacy. Compressing the two pathways into a single statement about "compounding" risks saying more than the FDA said.

For clinic owners, the useful reading is procedural. Watch for a final agency determination, check the status of the relevant drug on the shortage list when that condition matters, and ask which statutory pathway a supplier operates under. This story concerns the agency's proposal and its stated rationale at the time, not a finding that every existing patient prescription is unlawful or a prediction about a final rule.